Literature DB >> 19730094

Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis.

Håkan Morén1, Malin Malmsjö, Jes Mortensen, Arne Ohrström.   

Abstract

PURPOSE: To describe riboflavin and ultraviolet light (UV) collagen crosslinking as an effective treatment for infectious keratitis.
METHODS: A 25-year-old previously healthy female contact lens user was diagnosed with unilateral severe keratitis with unclear pathogenesis, although the clinical presentation suggested acanthamoeba as the infectious agent. A 4-mm diameter, annular, semi-opaque infiltrate was found on the paracentral parts of the cornea in the left eye (OS). Laboratory examinations for bacteria, herpes simplex, and acanthamoeba were performed, but no specific pathogen could be detected. Best corrected visual acuity (BCVA) at presentation was 20/1000. Treatment was initialized with broad-spectrum antibiotics also covering acanthamoeba. During the first month of treatment the keratitis progressed and the corneal thickness diminished. Therefore, treatment with riboflavin and UV collagen crosslinking was initiated.
RESULTS: After riboflavin and UV collagen crosslinking therapy, there was a rapid decrease of pain and necrotic material. Reepithelialization of the cornea started within a few days and was complete within a month. After 2 months, the wound had healed completely. Nine months after the UV treatment, BCVA was 20/30.
CONCLUSIONS: This case illustrates the positive effects of riboflavin and UV collagen crosslinking on presumed infectious keratitis with a satisfactory final visual outcome. This may be a promising new treatment for keratitis, although this remains to be elucidated in detail in future studies. Until more data are available this treatment should only be considered in therapy-refractive keratitis or ulceration and not in the first line of defence since it may have cytotoxic side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19730094     DOI: 10.1097/ICO.0b013e31819c4e43

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  35 in total

1.  Evaluation of combined riboflavin and ultraviolet A as an alternative treatment for keratitis.

Authors:  Zhen-Yong Zhang; Xing-Ru Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-14       Impact factor: 3.117

2.  Biomechanical property analysis after corneal collagen cross-linking in relation to ultraviolet A irradiation time.

Authors:  Elena Lanchares; María Angeles del Buey; José Angel Cristóbal; Laura Lavilla; Begoña Calvo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

Review 3.  Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies.

Authors:  Maria Gkika; Georgios Labiris; Vassilios Kozobolis
Journal:  Int Ophthalmol       Date:  2011-08-17       Impact factor: 2.031

Review 4.  The Development of Drugs against Acanthamoeba Infections.

Authors:  Ruqaiyyah Siddiqui; Yousuf Aqeel; Naveed Ahmed Khan
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 5.  Therapeutic and inducing effect of corneal crosslinking on infectious keratitis.

Authors:  Liang-Zhu Jiang; Shi-Yan Qiu; Zhi-Wei Li; Xiao Zhang; Xiang-Chen Tao; Guo-Ying Mu
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

6.  Collagen cross-linking for resistant corneal ulcer.

Authors:  Rana Sorkhabi; Mohamadreza Sedgipoor; Ali Mahdavifard
Journal:  Int Ophthalmol       Date:  2012-09-27       Impact factor: 2.031

7.  UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study.

Authors:  Karim Makdoumi; Jes Mortensen; Omid Sorkhabi; Bo-Eric Malmvall; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-27       Impact factor: 3.117

8.  Acanthamoeba migration in an electric field.

Authors:  Jolene Chang Rudell; Jing Gao; Yuxin Sun; Yaohui Sun; James Chodosh; Ivan Schwab; Min Zhao
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-21       Impact factor: 4.799

9.  Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Anders Magnuson; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-19       Impact factor: 3.117

10.  Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.

Authors:  G Pron; L Ieraci; K Kaulback
Journal:  Ont Health Technol Assess Ser       Date:  2011-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.